Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Wed, 07.08.2024
Formycon AG
Press Release // August 7, 2024
Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FWB: FYB) today announced details for the financial and earnings conference call for the first half of the 2024 fiscal year on August 13, 2 [ … ]
Tue, 30.07.2024
Formycon AG
Press Release // July 30, 2024
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Phase III “Lotus” trial compares safety and efficacy of FYB206 with reference drug Keytruda®1 (pembrolizumab)
The “Lotus” trial will involve the treatment of around 500 randomized NSCLC2 patients in various countries [ … ]
Fri, 26.07.2024
Formycon AG
Press Release // July 26, 2024
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommends approval of FYB202 for the treatment of severe inflammatory diseases in the fields of gastroente [ … ]
Mon, 01.07.2024
Formycon AG
Press Release // July 01, 2024
Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA") approved FYB203/AHZA [ … ]
Thu, 13.06.2024
Formycon AG
Press Release // June 13, 2024
Formycon reports on the results of the Annual General Meeting
Management provides detailed report on financial year 2023 and current company performance
Shareholders approve all agenda items and formally approve the acts of the members of the Management Board and Supervisory Board by large majority
Supervisory Boa [ … ]
Thu, 13.06.2024
Formycon AG
Press Release // June 13, 2024
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
First patient entered Phase I clinical trial “Dahlia” to compare the pharmacokinetics (PK), safety and tolerability of FYB206 with the reference product Keytruda®[i] (First Patient In).
"Dah [ … ]
Wed, 15.05.2024
Formycon AG
Presse Release // May 15, 2024
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Planegg-Martinsried – Klinge Biopharma GmbH ("Klinge"), licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to [ … ]
Wed, 15.05.2024
Formycon AG
Presse Release // May 15, 2024
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Planegg-Martinsried – Klinge Biopharma GmbH ("Klinge"), licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to [ … ]
Wed, 08.05.2024
Formycon AG
Press Release // May 8, 2024
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Group revenue amounts to € 17.7 million and corresponds to plan
Group EBITDA of € -5.5 million reflects investments in pipeline and corporate development
Adjusted Group EBITDA of € -1.2 million shows strong at-equi [ … ]
Tue, 07.05.2024
Formycon AG
Press release // 07 May 2024
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
Formycon proposes to the Annual General Meeting a more international focus and expansion of the Supervisory Board to five members
With Colin Bond, Dr. Bodo Coldewey and Nicholas Haggar, three new candidates with relevant industry and financial [ … ]